Davis Selected Advisers Sells 24,899 Shares of Solventum Co. (NYSE:SOLV)

Davis Selected Advisers trimmed its holdings in Solventum Co. (NYSE:SOLV) by 0.5% in the 4th quarter, Holdings Channel reports. The fund owned 5,246,614 shares of the company’s stock after selling 24,899 shares during the quarter. Solventum accounts for about 2.0% of Davis Selected Advisers’ investment portfolio, making the stock its 18th biggest position. Davis Selected Advisers’ holdings in Solventum were worth $346,591,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Modus Advisors LLC bought a new position in shares of Solventum in the 4th quarter worth about $25,000. Stonebridge Financial Group LLC bought a new stake in shares of Solventum in the 4th quarter worth approximately $26,000. True Wealth Design LLC boosted its position in shares of Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares in the last quarter. Crews Bank & Trust bought a new stake in shares of Solventum in the 4th quarter worth approximately $32,000. Finally, Prospera Private Wealth LLC bought a new position in shares of Solventum during the third quarter valued at $35,000.

Solventum Stock Performance

Shares of SOLV opened at $77.96 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The firm has a market capitalization of $13.47 billion and a P/E ratio of 28.35. The business has a fifty day moving average of $73.65 and a 200 day moving average of $70.55.

Analyst Ratings Changes

SOLV has been the subject of several analyst reports. Wells Fargo & Company raised their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Piper Sandler lifted their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Finally, Morgan Stanley upped their price target on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Solventum has a consensus rating of “Hold” and an average price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.